Tildipirosin

Tildipirosin
Clinical data
Trade names	Zuprevo
License data	US DailyMed: Tildipirosin ;
Routes of; administration	Intramuscular, subcutaneous
ATCvet code	QJ01FA96 ( WHO );
Legal status
Legal status	CA: ℞-only ; US: ℞-only ; EU:Rx-only;
Identifiers
	IUPAC name (4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4S,5S,6R)-4-(Dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-5,9,13-trimethyl-7-(2-piperidin-1-ylethyl)-15-(piperidin-1-ylmethyl)-1-oxacyclohexadeca-11,13-diene-2,10-dione; (4R,5S,6S,7R,9R,11E,13E,15R,16R)-16-Ethyl-4-hydroxy-5,9,13-trimethyl-2,10-dioxo-7-[2-(1-piperidinyl)ethyl]-15-(1-piperidinylmethyl)oxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-3-(dimethylamino)-β-D-glucopyranoside; ; ;
CAS Number	328898-40-4 ;
PubChem CID	24860548 ;
DrugBank	DB11470 ;
ChemSpider	30790722 ;
UNII	S795AT66JB ;
ChEMBL	ChEMBL3039509 ;
CompTox Dashboard (EPA)	DTXSID70954546 ;
ECHA InfoCard	100.168.011
Chemical and physical data
Formula	C41H71N3O8
Molar mass	734.032 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CC[C@@H]1[C@H](/C=C(/C=C/C(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O)N(C)C)O)CCN3CCCCC3)C)\C)CN4CCCCC4;
	InChI InChI=1S/C41H71N3O8/c1-8-35-32(26-44-20-13-10-14-21-44)23-27(2)15-16-33(45)28(3)24-31(17-22-43-18-11-9-12-19-43)40(29(4)34(46)25-36(47)51-35)52-41-39(49)37(42(6)7)38(48)30(5)50-41/h15-16,23,28-32,34-35,37-41,46,48-49H,8-14,17-22,24-26H2,1-7H3/b16-15+,27-23+/t28-,29+,30-,31+,32-,34-,35-,37+,38-,39-,40-,41+/m1/s1; Key:HNDXPZPJZGTJLJ-UEJFNEDBSA-N;

Last updated June 30, 2025

Tildipirosin, sold under the brand name Zuprevo, is a macrolide antibiotic used in pigs and cattle.^[1]^[3]

Medical uses

In the United States, tildipirosin is indicated for the treatment or control of bovine respiratory disease associated with Mannheimia haemolytica , Pasteurella multocida , and Histophilus somni in beef and non-lactating dairy cattle.^[1]

In the European Union, tildipirosin is indicated for the treatment and metaphylaxis of swine respiratory disease associated with Actinobacillus pleuropneumoniae , P. multocida, Bordetella bronchiseptica , and Glaesserella parasuis sensitive to tildipirosin;^[3] and for the treatment and prevention of bovine respiratory disease associated with M. haemolytica, P. multocida, and H. somni sensitive to tildipirosin.^[3]

References

1 2 3 "Zuprevo- tildipirosin injection, solution". DailyMed. U.S. National Library of Medicine. 11 January 2013. Retrieved 21 August 2023.
↑ Budde JA, McCluskey DM (2023). Plumb's Veterinary Drug Handbook (Tenth ed.). Wiley. p. 1235. ISBN 978-1-394-17220-7.
1 2 3 4 "Zuprevo EPAR". European Medicines Agency. 3 February 2022. Retrieved 21 August 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[Zuprevo_FDA_label-1] 1 2 3 "Zuprevo- tildipirosin injection, solution". DailyMed. U.S. National Library of Medicine. 11 January 2013. Retrieved 21 August 2023.

[2] Budde JA, McCluskey DM (2023). Plumb's Veterinary Drug Handbook (Tenth ed.). Wiley. p. 1235. ISBN 978-1-394-17220-7.

[Zuprevo_EPAR-3] 1 2 3 4 "Zuprevo EPAR". European Medicines Agency. 3 February 2022. Retrieved 21 August 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[1]

[2]

[3]